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COMBINED EMAIL AND IN OFFICE TECHNOLOGY IMPROVES PATIENT
REPORTED OUTCOMES COLLECTION IN STANDARD ORTHOPAEDIC
CARE
X. Zhou, R. Karia, R. Iorio, J. Zuckerman, J. Slover, P. Band. NYU Langone
Med. Ctr., Hosp. for Joint Diseases, New York, NY, United States
Purpose: Patient reported outcomes (PRO) provide an important
measure of clinical condition from the patient’s perspective. Recently,
there has been increasing interest in the use of PRO scores during
routine clinical practice, as the focus on quality and value-based
healthcare continues to grow. However, the routine collection of PRO
data without disrupting clinical workﬂow remains a challenge. This
study evaluates the capture rates of PRO data as part of standard
orthopaedic care, collected electronically via either e-mail or in the
ofﬁce setting.
Methods: An electronic PRO collection system was developed at a
large, tertiary, academic medical center in 2012, designed to routinely
collect PRO data as part of standard care. An e-mail distribution
function was built to send a secure HIPPA compliant e-mail to patients
three days before their visit. A PRO questionnaire link is embedded in
the e-mail allowing completion at home prior to the visit. Patients who
do not complete via e-mail receive a touchscreen in the ofﬁce to
complete the PRO questionnaire prior to their clinical exam. PRO
scores are calculated in real-time, integrated into the patient’s EMR,
and made available to the evaluating physician for clinical decision-
making.
Results: Between May, 1st, 2012 and April 30, 2013, PRO questionnaires
were completed for 19218 of 26548 total patient visits to 21 adult
reconstruction or sports medicine practices. Overall, completion rates
were 79% and 68%. Ofﬁce staff collected email addresses for 48% of total
patient visits, and consequently, 64% (12306 of 19218) of the completed
PRO questionnaires were done in the ofﬁce versus 36% (6912 of 19218)
via email. The completion rate via email was 41% in adult reconstruction
and 32% in sports medicine. When the email completion rate is calcu-
lated based on patients for whom ofﬁce staff obtained email addresses,
completion rates via email at home are 55% in adult reconstruction and
53% in sports medicine. Elderly patients (65 years) had a higher e-mail
completion rate (57%) than younger (<40 years) patients (52%), p <
0.001.
Conclusion: Electronic collection of PRO scores as part of standard
orthopaedic care is feasible, especially when both email and ofﬁce-
based collection methods are used. Older patients were more com-
pliant with email than younger patients. Email is a useful tool for
PRO collection in the orthopaedic outpatient setting, and ofﬁce staff
should work to obtain email addresses even from older patients,
who are more compliant with home email completion of surveys
than younger patients. Patients should be encouraged to complete
PRO questionnaires via email to minimize disruption to ofﬁce clinical
workﬂow.
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CORRELATION BETWEEN ROUTINE ASSESSMENT OF PATIENT INDEX
DATA 3 (RAPID3) ANDWOMAC IN ROUTINE CARE IN PATIENTS WITH
KNEE OSTEOARTHRITIS
A. Lurati, D. Bompane, K. Re, M. Marrazza, M. Scarpellini. Rheumatology
Unit Fornaroli Hosp., Magenta, Italy
Objective: To compare Routine Assessment of Patient Index Data 3
(RAPID3) on a Multidimensional Health Assessment Questionnaire
(MDHAQ) with the Western Ontario and Mc-Master Universities
Osteoarthritis Index (WOMAC) in patients with knee osteoarthritis and
to evaluate its reliability.
Methods: Consecutive patients with symptomatic knee osteoarthritis
(VAS >50 mm) based on ACR Classiﬁcation criteria were enrolled. A
radiological Kellgren-Lawrence index 1–2 was required. Correlation
between indices was estimated with Spearman’s Rho. A General Linear
Model (GLM) was used to estimate the effect size between indices.
Reliability analysis was assessed ﬁnally using coefﬁcients of IntraClass
Correlation.
Results: 221 patients were enrolled and completed WOMAC and
MDHAQ-RAPID3 questionnaires during the period 2009–2013. RAPID
3 mean value was 5.7  1.3 in patients with knee OA. Kurtosis
0.287  0.211, skewness 0.61  0.12. The ceiling/ﬂoor effect, % of
responses that are coded at the maximum/minimum value, ranged<10%. WOMAC total score was 57.2  13.4. Spearman’s rho index
was 0.84. Using a General Linear Model (GLM) to estimate the
proportion of variation of WOMAC explained by RAPID 3 we found
an effect size of 0.82 (p < 0.01). Coefﬁcients of IntraClass Correlation
between mean values of WOMAC and RAPID3 was 0.812, F test with
P ¼ 0.001.
Conclusion: RAPID3 scores provide similar quantitative information to
WOMAC in patients with knee osteoarthritis.Clinical Trials
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COST-UTILITY OF EXERCISE THERAPY ADDED TO GENERAL
PRACTITIONERS’ CARE VERSUS GENERAL PRACTITIONERS’ CARE
ALONE IN PATIENTS WITH HIP OSTEOARTHRITIS
S. Tan y, C. Teirlinck z, J. Dekker x, A. Bohnen z, P. van Es z, J. Verhaar z,
B. Koes z, S. Bierma-Zeinstra z, P. Luijsterburg z, M. Koopmanschap y.
y Erasmus Univ. Rotterdam, Rotterdam, Netherlands; z Erasmus MC,
Erasmus Univ. Med. Ctr., Rotterdam, Netherlands; xVU Med. Ctr./EMGO
Inst., Amsterdam, Netherlands
Purpose: To determine the cost-effectiveness over a period of 12
months of exercise therapy added to general practitioners’ care com-
pared to general practitioners’ care alone in patients with a new episode
of hip OA in general practice.
Methods: A cost-utility study was performed in conjunction with a
multi-center randomized controlled trial with a parallel group
design. Patients participated if they were 45 years or older, comply
with the clinical American College of Rheumatology criteria for hip
OA, and visited their general practitioner (GP) for a new episode of
complaints due to hip osteoarthritis. Patients were excluded if they:
1) were already treated with exercise therapy in the present epi-
sode of hip OA, 2) had a hip pain score of <2 on the 11-point
numeric rating scale (0 to 10), 3) had a high level of physical
function, a score of <2 on the walking ability and the physical
function sections of the Algofunctional index, 4) had undergone hip
surgery or on the waiting list, 5) had severe disabling co-morbidity
and 6) had insufﬁcient comprehension of the Dutch language and/
or were mentally incapable of participation.
The patients were allocated at random in two treatment groups: one
group received exercise therapy supervised by a physiotherapist (up to
15 sessions in the ﬁrst 3 months and 3 follow-up sessions in month 5, 7
and 9) added to GP care and the control group received GP care only.
The cost-utility study was primarily conducted from a societal per-
spective, but the healthcare perspective was also applied. Data on direct
medical costs, productivity costs and quality of life was collected at
baseline and at 6, 13, 26, 39 and 52 weeks follow-up. Annual costs were
determined by adding up the costs per period. The costs for the time
between the measurement periods (week 6–7) were established
through linear interpolation. All costs were based on Euro 2011 cost
data. The quality of life score per patient during the 52 weeks follow up
was estimated by combining the EQ-5D scores at all measurement
moments. Differences between the intervention and control group
were assessed by means of the independent sample T test (for variables
showing a normal distribution), the MannWhitney U test (for variables
not normally distributed) or Pearson Chi-square test (for variable
fractions). Using nonparametric bootstrapping (drawing 2,500 obser-
vations at random), the degree of uncertainty for costs and health
effects and the cost-utility ratio was examined on the so-called CE-
plane. In addition, an acceptability curve was generated to indicate the
probability that the intervention has lower incremental costs per
quality adjusted life year (QALY) gained than various thresholds for the
maximum willingness to pay for an extra QALY.
Results: The study took place in the period 2009–2012 and ﬁnally
203 patients were included. The annual direct medical costs per
patient were signiﬁcantly lower for the exercise group (V 1,233)
compared to the control group (V 1,331) despite additional physi-
otherapy visits. The average annual societal costs per patient were
lower in the exercise group (V 2,634 versus V 3,241; P ¼ 0,002).
Productivity costs were higher than direct medical costs. Patients in
the exercise group experienced a slightly, but not signiﬁcantly,
higher quality of life (0.776 versus 0.770). We found a societal
average cost effectiveness (CE)-ratio of – V 107,505 per quality
adjusted life year (exercise cost effective). When only direct medical
Abstracts / Osteoarthritis and Cartilage 22 (2014) S57–S489S192costs were included, the average cost per quality adjusted life year
amounted to V 17,441, but the uncertainty around both CE-ratios
was substantial.
Conclusions: Over a period of 52 weeks, with a CE-ratio of – V 107,505
per QALY from the societal perspective and a CE-ratio of V 17,441 per
QALY from the healthcare perspective, our study revealed a consid-
erable probability that exercise therapy added to GP care is cost saving
or cost effective as compared to GP care alone.
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RESULTS FROM A SINGLE CENTER, DOUBLE-BLIND, RANDOMIZED,
PLACEBO-CONTROLLED, PARALLEL-GROUP STUDY OF THE
EFFICACY AND SAFETY OF INTRA-ARTICULAR
ONABOTULINUMTOXINA FOR OSTEOARTHRITIS KNEE PAIN
K.C. Kalunian y, L. Arendt-Nielsen z, C.C. Turkel x, R. DeGryse x,
T.E. McAlindon k, A.J. Boon{, G.-L. Jiang x. yDept. of Med., Div. of
Rheumatology, Allergy, & Immunology, Univ. of California, San Diego, La
Jolla, CA, United States; zAalborg Univ., Sch. of Med., Ctr. for Sensory-
Motor Interaction, Aalborg E, Denmark; xAllergan, Inc., Irvine, CA,
United States; kDiv. of Rheumatology & Immunology, Tufts Med. Ctr.,
Boston, MA, United States; {Dept. of Physical Med. & Rehabilitation,
Dept. of Neurology, Mayo Clinic, Rochester, MN, United States
Purpose: The peripheral release of inﬂammatory mediators may sen-
sitize nociceptors, provoke central sensitization, and facilitate clinical
pain. Inhibition of the peripheral manifestations in knee osteoarthritis
(OA) by onabotulinumtoxinA (onabotA) may reduce the drive, central
consequences, and eventually clinical pain. Study objectives were to
determine the safety and efﬁcacy of a single intra-articular (IA) onabotA
injection in patients (pts) with painful knee OA.
Methods: Pts 40–75 y with knee OA (American College of Rheumatol-
ogy modiﬁed clinical classiﬁcation criteria; Kellgren-Lawrence grade I-
III) were enrolled in this 16-wk, single-center, double-blind, random-
ized, placebo-controlled, parallel-group phase 1b study. Pts were
stratiﬁed by baseline 14-day average daily worst pain score (ADWP;
4.0–9.0 [0–10 numeric rating scale]), and randomized (1:1) to ultra-
sound-guided injection of either onabotA (200 U) or placebo (saline).
Pts recorded worst daily pain for 2 wks before and 12 wks after injec-
tion (study visits: 1, 4, 8, 12 wks).
The planned primary efﬁcacy assessment was 14-day ADWP score
change from baseline, jointly analyzed for wks 4, 8, and 12 by repeated
measures analysis of covariance (RMANCOVA); secondary planned
efﬁcacy outcomes included Western Ontario McMaster (WOMAC) OA
Index (total, pain, and physical function scores) and pt global
impression of change (GIC). Other planned outcomes included the
PainDETECT questionnaire (PD-Q), assessed at baseline and each visit.
3 pain subtypes have been deﬁned by total PD-Q score: nociceptive
(PD-Q score 12), neuropathic (19), and uncertain (13 and 18).
Unplanned post-hoc analyses of primary and secondary outcomes by
baseline PD-Q pain subtype were performed. Safety data were col-
lected, including muscle strength around the knee (knee extension/
ﬂexion, ankle dorsiﬂexion/plantarﬂexion) for the study side and the
contralateral side.
The primary efﬁcacy assessment (intent-to-treat population) was ana-
lyzed using RMANCOVA for between-group comparisons, adjusted for
baseline ADWP score. Secondary efﬁcacy variables were analyzed with
a Wilcoxon rank-sum test; WOMAC analyses did not use a baseline
covariate. The safety population included all pts who received drug. All
randomized pts received the assigned drug.
Results: Of 170 screened pts, 121 were randomized to onabotA (n ¼ 61)
or placebo (n¼ 60). Mean agewas 62.3 y, all Caucasian, and comparable
male (n ¼ 59) and female (n ¼ 62) participation. No clinically relevant
between-group differences were observed at baseline.
The primary efﬁcacy analysis yielded no signiﬁcant difference between
onabotA and placebo for the change from baseline in ADWP score to the
3 prospectively deﬁned time points (P ¼ 0.70). Between-group differ-
ences were also not signiﬁcant for ADWP score change from baseline to
each individual time point (each of wks 2–12), WOMAC (total index,
pain, or physical function scores at wks 1, 4, 8, 12), or GIC (wks 1, 4, 8,
12). Post-hoc analyses by PD-Q pain subtype found numerically greater
improvement for all efﬁcacy outcomes among pts with nociceptive pain
(PD-Q12) who received onabotA (n ¼ 36) versus placebo (n ¼ 32)
across all time points (Figure); signiﬁcant differences were seen at wk 8
and/or 12 for all WOMAC outcomes and GIC.Adverse events (AEs) were reported for 24 pts (39.3%) receiving ona-
botA and 27 pts (45.0%) receiving placebo. Treatment-related AEs were
reported for both onabotA (arthralgia, n¼ 1 [1.6%]; burning sensation, n
¼ 1 [1.6%]) and placebo (n ¼ 1 [1.7%] each: arthralgia, arthropathy,
hypoaesthesia, joint stiffness, joint warmth, muscular weakness); all
were mild. Muscle strength evaluations found no decrease from base-
line in any knee or ankle extension/ﬂexion measure in either group at
any visit.
Conclusion: This exploratory study found no signiﬁcant between-
group differences in primary or secondary efﬁcacy endpoints;
improvement from baseline was observed for both treatment groups.
Post-hoc analyses found numerically greater improvement for all efﬁ-
cacy endpoints among the PD-Q nociceptive pain subtype that received
onabotA versus placebo, suggesting the PD-Q may be useful in identi-
fying onabotA-responsive pts with knee OA pain. Locally administered
onabotA (200 U IA) had an acceptable safety proﬁle and did not
decrease muscle strength around the knee. Further evaluation of ona-
botA efﬁcacy among pts with nociceptive knee OA pain is needed to
conﬁrm these post-hoc ﬁndings.
Disclosure: Funded by Allergan.331
PHYSIOTHERAPIST-DELIVERED EXERCISE AND PAIN COPING SKILLS
TRAINING IS MORE EFFECTIVE THAN EITHER INTERVENTION
ALONE IN KNEE OSTEOARTHRITIS
K.L. Bennell y, Y. Ahamed y, C. Bryant z, G. Jull x, M. Hunt k, J. Kenardy x,
A. Forbes{, M. Akram{, A. Harris{, M. Nicholas #, B. Metcalf y,
T. Egerton y, F. Keefe yy. yCtr. for Hlth., Exercise & Sports Med., University
of Melbourne, Australia; zUniv. of Melbourne, Melbourne, Australia; xUniv.
of Queensland, Brisbane, Australia; kUniv. of British Columbia, Vancouver,
BC, Canada; {Monash Univ., Melbourne, Australia; #Univ. of Sydney,
Sydney, Australia; yyDuke Univ. Sch. of Med., Durham, NC, United States
Purpose: Pain is often the primary symptom of knee osteoarthritis (OA)
and results from a complex interaction between structural changes,
physical impairments and psychological factors. Much evidence sup-
ports the beneﬁts of strengthening exercise in this patient population.
There is also limited research supporting psychologist-delivered pain
coping skills training (PCST), a form of cognitive behavioural therapy, in
knee OA. Though typically provided separately, there are potential
symptom-, resource- and personnel-advantages of exercise and PCST
being delivered together by a single healthcare professional. Physi-
otherapists are a logical choice to be trained to deliver a PCST inter-
vention as they already have expertise in administering exercise and are
cognisant of the need for a biopsychosocial approach to management.
This study aimed to investigate whether an integrated 12-week exercise
and PCST treatment program delivered by physiotherapists is more
efﬁcacious than either program alone in treating pain and physical
function in individuals with knee OA.
Methods: The study utilized a 3-arm randomized controlled trial design
with measurements taken by a blinded assessor at baseline, 12, 32 and
52weeks following randomization. Twelveweeks was the primary time
